Clearing the clouds: Case-report and review of the literature.


Journal

Seminars in dialysis
ISSN: 1525-139X
Titre abrégé: Semin Dial
Pays: United States
ID NLM: 8911629

Informations de publication

Date de publication:
01 2021
Historique:
pubmed: 4 11 2020
medline: 29 10 2021
entrez: 3 11 2020
Statut: ppublish

Résumé

In peritoneal dialysis (PD), a cloudy dialysate is an alarming finding. Bacterial peritonitis is the most common cause, however, atypical infections and non-infectious causes must be considered. A 46-year-old man presented with asthenia, paraesthesia, foamy urine and hypertension. Laboratory testing revealed severe azotaemia, anaemia, hyperkalaemia and nephrotic-range proteinuria. Haemodialysis was started through a central venous catheter. Later, due to patient preference, a Tenckhoff catheter was inserted. Conversion to PD occurred 3 weeks later, during hospitalization for a presumed central line infection. A month later, the patient was hospitalized for neutropenic fever. He was diagnosed an acute parvovirus infection and was discharged under isoniazid for latent tuberculosis. Four months later, the patient presented with fever and a cloudy effluent. Peritoneal fluid (PF) cytology was suggestive of infectious peritonitis, but the symptoms persisted despite antibiotic therapy. Bacterial and mycological cultures were negative. No neoplastic cells were detected. Mycobacterium tuberculosis eventually grew in PF cultures, despite previous negative molecular tests. Directed therapy was then initiated with excellent response. Thus, facing a cloudy effluent, one must consider multiple aetiologies. Diagnosis of peritoneal tuberculosis is hampered by the lack of highly sensitive and specific exams. Here, diagnosis was only possible due to positive mycobacterial cultures.

Identifiants

pubmed: 33140512
doi: 10.1111/sdi.12931
doi:

Substances chimiques

Anti-Bacterial Agents 0
Dialysis Solutions 0

Types de publication

Case Reports Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

83-88

Informations de copyright

© 2020 Wiley Periodicals LLC.

Références

Rocklin MA, Teitelbaum I. Noninfectious causes of cloudy peritoneal dialysate. Semin Dial. 2001;14(1):37-40.
Teitelbaum I. Cloudy peritoneal dialysate: it’s not always infection. Contrib Nephrol. 2006;150(table 1):187-194.
Li P-T, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int. 2016;36(5):481-508.
Rohit A, Abraham G. Peritoneal dialysis related peritonitis due to Mycobacterium spp.: a case report and review of literature. J Epidemiol Glob Health. 2016;6(4):243-248. https://doi.org/10.1016/j.jegh.2016.06.005
Sriperumbuduri S, Zimmerman D. Cloudy dialysate as the initial presentation for lymphoma. Case Reports Nephrol. 2018;2018:1-2.
Bargman JM, Zent R, Ellis P, Auger M, Wilson S. Diagnosis of lymphoma in a continuous ambulatory peritoneal dialysis patient by peritoneal fluid cytology. Am J Kidney Dis. 1994;23(5):747-750. https://doi.org/10.1016/S0272-6386(12)70289-5
Daugirdas JT, Leehey DJ, Popli S, et al. Induction of peritoneal fluid eosinophilia and/or monocytosis by intraperitoneal air injection. Am J Nephrol. 1987;7(2):116-120.
Shigemoto E, Mizuno M, Suzuki Y, et al. Increase of eosinophil in dialysate during induction of peritoneal dialysis. Perit Dial Int. 2019;39(1):90-92.
Yoshimoto K, Saima S, Echizen H, Nakamura YIT. A drug-induced turbid peritoneal dialysate in five patients treated with continuous ambulatory peritoneal dialysis. Clin Nephrol. 1993;40(2):114-117.
Yoshimoto K, Saima S, Nakamura Y, et al. Dihydropyridine type calcium channel blocker-induced turbid dialysate in patients undergoing peritoneal dialysis. Clin Nephrol. 1998;50(2):90-93.
Goel S, Misra M, Rajiv Saran RK. The rationale for, and role of, heparin in peritoneal dialysis. Adv Perit Dial. Available from https://www.advancesinpd.com/adv98/98-2c-25therationeal.html
Hsiao P-J, Lin H-W, Sung C-C, Wang C-W, Chu P, Lin S-H. Incidence and clinical course of lercanidipine-associated cloudy effluent in continuous ambulatory peritoneal dialysis. Clin Nephrol. 2010;74(3):217-222.
Touré F, Lavaud S, Mohajer M, et al. Icodextrin-induced peritonitis: study of five cases and comparison with bacterial peritonitis. Kidney Int. 2004;65(2):654-660.
Tzvi-Behr S, Frishberg Y, Ben-Shalom E, Rinat C, Becker-Cohen R. Eosinophilia in a peritoneal dialysis patient: answers. Pediatr Nephrol. 2018;33(9):1507-1508.
Kohn OF, Culbertson S, Becker YT. Hemoperitoneum in a peritoneal dialysis patient: ruptured ectopic pregnancy. Perit Dial Int. 2018;38(6):455-456.
Freitas C, Rodrigues A, Carvalho MJ, Cabrita A. Chemical peritonitis in a patient treated with icodextrin and intraperitoneal vancomycin. Nefrologia. 2011;31(5):625-626.
Pinerolo MC, Porri MT, D’Amico G. Recurrent: sterile peritonitis at onset of treatment with icodextrin solution. Perit Dial Int. 1999;19(5):491-492.
Goffin E. Aseptic peritonitis and icodextrin. Perit Dial Int. 2006;26(3):314-316.
Tintillier M, Pochet J-M, Christophe J-L, Scheiff J-M, Goffin E. Transient sterile chemical peritonitis with icodextrin: clinical presentation, prevalence, and literature review. Perit Dial Int. 2002;22(4):534-536.
Tzamaloukas AH, Obermiller LE, Gibel LJ, et al. Peritonitis associated with intra-abdominal pathology in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 1993;13:335-337. https://doi.org/10.1177/089686089301302S83
Talwani R, Horvath JA. Tuberculous peritonitis in patients undergoing continuous ambulatory peritoneal dialysis : case report and review. Clin Infect Dis. 2016;31(1):70-75. http://www.jstor.org/stable/4482262
Vachharajania T, Abreo K, Phadkea A, Oza U, Kirpalania A. Diagnosis and treatment of tuberculosis in hemodialysis and renal transplant patients. Am J Nephrol. 2000;20:273-277.
Cengiz K. Increased incidence of tuberculosis in patients undergoing hemodialysis. Nephron. 1996;73:421-424.
Naqvi A, Akhtar F, Naqvi R, et al. Problems of diagnosis and treatment of tuberculosis following renal transplantation. Transplant Proc. 1997;29(7):3051-3052.
Sundaram M, Das AS, John GT, Kekre NS. Tuberculosis in renal transplant recipients. Indian J Urol. 2008;24(3):396-400.
Ram R, Swarnalatha G, Akpolat T, Dakshinamurty KV. Mycobacterium tuberculous peritonitis in CAPD patients: A report of 11 patients and review of literature. Int Urol Nephrol. 2013;45(4):1129-1135.
Wu DC, Averbukh LD, Wu GY. Diagnostic and therapeutic strategies for peritoneal tuberculosis. a review. J Clin Transl Hepatol. 2019;7(X):1-9.
Kohli M, Schiller I, Dendukuri N, et al. Xpert ® MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance (review). Cochrane Libr. 2018;(8).
Sanai FM, Bzeizi KI. Systematic review: tuberculous peritonitis - presenting features, diagnostic strategies and treatment. Aliment Pharmacol Ther. 2005;22(8):685-700.
Chang TI, Kim HW, Park JT, et al. Early catheter removal improves patient survival in peritoneal dialysis patients with fungal peritonitis: Results of ninety-four episodes of fungal peritonitis at a single center. Perit Dial Int. 2011;31(1):60-66.
Worawat Chumpangern WR, Isoniazid-resistant tuberculosis: WHO treatment guidelines. KKU J Med. 2018;4:1-9.
Quantrill SJ, Woodhead MA, Bell CE, Hutchison AJ, Gokal R. Peritoneal tuberculosis in patients receiving continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2001;16(5):1024-1027.
Sendi P, Friedl A, Graber P, Zimmerli W. Reactivation of dormant microorganisms following a trauma. Neth J Med. 2008;66(8):363.
DuBrow EL, Landis FB. Reactivation of pulmonary tuberculosis due to trauma. Chest. 1975;68(4):596-598. https://doi.org/10.1378/chest.68.4.596

Auteurs

Miguel Relvas (M)

Nephrology Department, Centro Hospitalar e Universitário de São João, Oporto, Portugal.
Nephrology & Infectious Diseases R&D, i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Oporto, Portugal.

Ana Beco (A)

Nephrology Department, Centro Hospitalar e Universitário de São João, Oporto, Portugal.
Nephrology & Infectious Diseases R&D, i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Oporto, Portugal.

Luciano Pereira (L)

Nephrology Department, Centro Hospitalar e Universitário de São João, Oporto, Portugal.
Nephrology & Infectious Diseases R&D, i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Oporto, Portugal.

Ana Oliveira (A)

Nephrology Department, Centro Hospitalar e Universitário de São João, Oporto, Portugal.
Nephrology & Infectious Diseases R&D, i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Oporto, Portugal.

José Silvano (J)

Nephrology Department, Centro Hospitalar e Universitário de São João, Oporto, Portugal.
Nephrology & Infectious Diseases R&D, i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Oporto, Portugal.

Rui Silva (R)

Nephrology Department, Centro Hospitalar e Universitário de São João, Oporto, Portugal.
Nephrology & Infectious Diseases R&D, i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Oporto, Portugal.

Nídia Marques (N)

Nephrology Department, Centro Hospitalar e Universitário de São João, Oporto, Portugal.
Nephrology & Infectious Diseases R&D, i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Oporto, Portugal.

Lurdes Santos (L)

Nephrology & Infectious Diseases R&D, i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Oporto, Portugal.
Infectious Diseases Department, Centro Hospitalar e Universitário de São João, Oporto, Portugal.

Luís Coentrão (L)

Nephrology Department, Centro Hospitalar e Universitário de São João, Oporto, Portugal.
Nephrology & Infectious Diseases R&D, i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Oporto, Portugal.

Manuel Pestana (M)

Nephrology Department, Centro Hospitalar e Universitário de São João, Oporto, Portugal.
Nephrology & Infectious Diseases R&D, i3S - Instituto de Investigação e Inovação em Saúde da Universidade do Porto, Oporto, Portugal.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH